Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
sipuleucel-T + leuprolide acetate
- Development stage
- Unknown
- Lead developer
- Dendreon
- Modality
- Dendritic Cell Vaccines → Immune Effector Cells → Other Cell Types → Cell Therapies, Small Molecules, Vaccines & Immunotherapeutics
- Administration
- Intravenous, Subcutaneous, Intramuscular
01
Overview
Sipuleucel-T + leuprolide acetate is a combination therapy where sipuleucel-T is an autologous cellular immunotherapy (cancer vaccine) indicated for metastatic castration-resistant prostate cancer (mCRPC), and leuprolide acetate is a synthetic gonadotropin-releasing hormone (GnRH/LHRH) agonist used for androgen deprivation. Sipuleucel-T activates patient-derived antigen-presenting cells with a recombinant fusion protein (PA2024; prostatic acid phosphatase linked to GM-CSF) to provoke a T-cell immune response targeted against prostate cancer cells expressing PAP. Leuprolide acetate induces testosterone suppression by downregulating the pituitary-gonadal axis, assisting in the underlying hormone-refractory disease setting[1][2][3].
- Brand names
- ProvengeLupron Depot
- Other names
- autologous cellular immunotherapy + luteinizing hormone-releasing hormone agonistcancer vaccine + LHRH agonist
02
Targets
PAP (Prostatic acid phosphatase)GnRHR (Gonadotropin-releasing hormone receptor)
Beyond the preview
Go deeper on sipuleucel-T + leuprolide acetate.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on sipuleucel-T + leuprolide acetate.